A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer

A Phase 1 Dose Escalation Trial Of CP-675,206 In Combination With Gemcitabine In Patients With Chemotherapy Naive Metastatic Pancreatic Cancer

The purpose of this study is to determine the safety and tolerability of different doses of CP-675,206 in combination with gemcitabine and to determine the maximum dose of CP-675,206 that is well tolerated when given in combination with gemcitabine to patients with advanced pancreatic cancer.

Inclusion Criteria:

• Patients with metastatic pancreatic cancer
• Patient must have adequate bone marrow, liver and kidney function
• Patient must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1
• Chemotherapy naive
• Inoperable pancreatic cancer

Exclusion Criteria:

• Patient must not have received prior systemic therapy for pancreatic cancer
• Patient must not have previously received anti-CTLA4 therapy
• History of chronic inflammatory or autoimmune disease